本文選題：替格瑞洛　切入點：冠心病　出處：《臨床軍醫(yī)雜志》2016年05期

【摘要】：正冠心病是一種猝死率高、危害嚴(yán)重的常見疾病,規(guī)范冠心病管理是改善預(yù)后、降低死亡率的關(guān)鍵,無論采取藥物或介入治療,抗血小板治療均是冠心病管理的基石。雙聯(lián)抗血小板,即阿司匹林聯(lián)合一種P2Y_(12)受體拮抗劑是急性冠狀動脈綜合征(acute coronary syndromes,ACS)和(或)經(jīng)皮冠狀動脈介入(percutaneous coronary intervention,PCI)患者的標(biāo)準(zhǔn)治療。替格瑞洛是一種新型強(qiáng)效
[Abstract]:Positive coronary heart disease is a common disease with high sudden death rate and serious harm. Standardized management of coronary heart disease is the key to improve prognosis and reduce mortality. Antiplatelet therapy is the cornerstone of coronary heart disease management no matter taking drugs or interventional therapy.Dual antiplatelet, or aspirin combined with a P2YS-1 receptor antagonist, is the standard treatment for patients with acute coronary syndrome (ACS) and / or percutaneous coronary intervention (coronary interventionn).Tigrilo is a new type of strong effect.
【作者單位】： 中國醫(yī)師協(xié)會心血管內(nèi)科醫(yī)師分會血栓防治專業(yè)委員會;中華醫(yī)學(xué)會心血管病分會介入學(xué)組;中華心血管病雜志編輯委員會;
【分類號】：R972
，

本文編號：1715927